Products
Otlertuzumab Biosimilar scFv-Fc Fusion Protein (CD37) for Research
Pre-Made Otlertuzumab biosimilar, di-scFv+Fc, Anti-CD37 Antibody: Anti-GP52-40/TSPAN26 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Otlertuzumab (TRU-016) is a humanized monoclonal antibody that targets CD37 designed for the treatment of cancer.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-416-1mg | 1mg | |
| GMP-Bios-ab-416-10mg | 10mg | |
| GMP-Bios-ab-416-100mg | 100mg | |
| GMP-Bios-ab-416-xmg | ＞100mg |
Product Details
| Products Name (INN Index) | Pre-Made Otlertuzumab biosimilar, di-scFv+Fc, Anti-CD37 Antibody: Anti-GP52-40/TSPAN26 therapeutic antibody |
| INN Name | Otlertuzumab |
| Target | CD37 |
| Format | di-scFv+Fc |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2013 |
| Year Recommended | 2014 |
| Companies | Trubion Pharmaceuticals;Aptevo Therapeutics |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Peripheral T-cell lymphoma |
| Development Tech | ADAPTIR Monospecific Platform |
About target - CD37
1. Protein Leukocyte antigen CD37
2. Gene CD37
3. Organism Homo sapiens (Human)
Function
Enzyme and pathway databases
PathwayCommons P11049
